Lux Biosciences’ Investigational Therapy for Uveitis, Luveniq™,
to be Featured at 7th International Symposium on Uveitis

Aspects of the Ongoing LUMINATE Phase 2/3 Clinical Study Program to Be Presented

JERSEY CITY, N.J. (September 10, 2008): Lux Biosciences today announced that details from the ongoing phase 2/3 LUMINATE clinical program of the company’s investigational therapy for uveitis, Luveniq™ (oral formulation of voclosporin), will be the subject of a presentation at the 7th International Symposium on Uveitis. The Symposium, organized by the International Uveitis Study Group, is being held from September 9 – 12 in Lake Constance, Germany.

Prof. Talin Barisani-Asenbauer, of the University of Vienna, will make the presentation “Patient Demographic Data for Phase 2/3 Clinical Trials of a Novel Calcineurin Inhibitor, Luveniq™, for the Treatment of Non-Infectious Uveitis” on behalf of the LUMINATE Study Group on Friday, September 12, from 8:15 am – 9:30 am, in the Symposium: New Drugs.

The LUMINATE clinical program, for which patient enrollment was completed in June, comprises three protocols. Across the two protocols that examine predominantly posterior manifestations of uveitis, 16.8% of patients enrolled had a diagnosis of posterior, 26.7% of intermediate and 45.2% of panuveitis. In the protocol that looks
at predominantly anterior manifestations of the disease, 50.5% of patients enrolled had a diagnosis of severe anterior uveitis and 31.8% had a diagnosis of panuveitis. The LUMINATE studies included participation at 56 sites in North America, Europe and India. The geographic spread among all patients in the program is 33.4% North America, 24.2% Europe, and 42.4% India.

“Overall, the LUMINATE study population appears to reflect the typical epidemiological pattern of the forms of non-infectious, sight-threatening uveitis requiring systemic treatment that is the target market for Luveniq™,” said Ulrich Grau, Lux Biosciences President and Chief Executive Officer.

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company focused on ophthalmic diseases. The company has a staged product portfolio of potentially first-in-class therapies distinguished by their short-term path to commercialization and potential to generate high revenue growth. The portfolio includes:

• Two Phase 3 clinical-stage projects including: i) Luveniq™, the oral formulation of a next-generation calcineurin inhibitor (voclosporin) developed as steroid-sparing therapy for the treatment of non-infectious uveitis, and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye for the prevention of rejection in corneal transplant recipients. Both the LUMINATE pivotal clinical program for Luveniq™ for the treatment of uveitis, as well as the LUCIDA (Lux Corneal Transplant Implant Development and Advancement of Therapy) pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007 and include sites in North America, Europe and India. Enrollment in the LUMINATE program was completed in June 2008.

• LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in late 2008. LX214 is based on Lux’ proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.

• Several earlier stage projects based on proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company’s website at http://www.luxbio.com.

###

CONTACTS:

Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com

Joan Kureczka
Kureczka/Martin Associates
+1 415 821 2413
Jkureczka@comcast.net